Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ427,5429,50,58
KB536537-0,37
PKN65,2265,340,59
Msft-1,08
Nokia2,86252,8655-2,19
IBM114,08117,990,00
Daimler AG27,2227,23-3,27
PFE33,6233,910,00
08.04.2020 10:38:00
Indexy online
AD Index online
select
AD Index online
 

  • 08.04.2020 10:25:00
Galapagos (GLPG.BR, Brussels)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
181,15 0,64 1,15 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 08.04.2020
Popis společnosti
Obecné informace
Název společnostiGalapagos NV
TickerGLPG
Kmenové akcie:Ordinary Shares
RICGLPG.AS
ISINBE0003818359
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.09.2019
Počet zaměstnanců k 30.09.2019 918
Akcie v oběhu k 30.09.2019 61 953 831
MěnaEUR
Kontaktní informace
UliceGeneraal De Wittelaan 3
MěstoMALINES (MECHELEN)
PSČ2800
ZeměBelgium
Kontatní osoba 
Funkce kontaktní osoby 
Telefon3 215 342 900
Fax3215342901

Business Summary: Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2019, Galapagos NV revenues increased from EUR205.1M to EUR752.5M. Net income applicable to common stockholders totaled EUR265.3M vs. loss of EUR44.2M. Revenues reflect R&D segment increase from EUR174.8M to EUR718.4M. Net Income reflects R&D segment income totaling EUR420M vs. loss of EUR38.2M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.88 to EUR4.08.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 08.04.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Executive Committee, Chief Executive Officer, Executive DirectorOnno van de Stolpe6001.01.1999
Member of the Executive Committee, Chief Financial Officer, Chief Operating OfficerBart Filius4901.12.2014
Member of the Executive Committee, Chief Scientific OfficerPiet Wigerinck5518.04.201201.04.2008
Member of the Executive Committee, Chief Medical OfficerWalid Abi-Saab54
Member of the Executive Committee, Chief Business OfficerAndre Hoekema62